Drug class
Small interfering RNA (siRNA) targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA
Mechanism of action
A GalNAc-conjugated double-stranded siRNA is taken up by hepatocytes and directs RNA-induced silencing complex (RISC)-mediated degradation of PCSK9 mRNA, reducing hepatic PCSK9 protein and increasing LDL-receptor recycling and LDL-cholesterol clearance.
General use cases
- Adjunct to diet and exercise to reduce LDL-cholesterol in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia and clinical atherosclerotic cardiovascular disease, under the applicable product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
